Breaking Finance News

Zacks Investment Research downgraded Mediwound Ltd (NASDAQ:MDWD) to Sell in a report released today.

Zacks Investment Research has downgraded Mediwound Ltd (NASDAQ:MDWD) to Sell in a report released on Wednesday October 05, 2016.

Previously on 8/17/2016, Wells Fargo & Co. reported on Mediwound Ltd (NASDAQ:MDWD) increased the target price from $0.00 to $14.00. At the time, this indicated a possible upside of 0.72%.

Just yesterday Mediwound Ltd (NASDAQ:MDWD) traded -1.06% lower at $7.57. Mediwound Ltd’s 50-day moving average is $7.71 and its 200-day moving average is $7.79. The last closing price is down -4.18% from the 200-day moving average, compared to the Standard & Poor's 500 Index which has decreased -0.01% over the same time period. 56,996 shares of MDWD traded hands, up from an average trading volume of 26,994

Recent Performance Chart

Mediwound Ltd (NASDAQ:MDWD)

Mediwound Ltd has 52 week low of $5.66 and a 52 week high of $10.47 and has a market capitalization of $0.

In addition to Zacks Investment Research reporting its stock price target, a total of 5 brokers have issued a research note on the company. The average stock price target is $15.00 with three equity analysts rating the company a strong buy, one equity analyst rating the company a buy, zero equity analysts rating the company a hold, zero firms rating the stock a underperform, and finally 0 firms rating the stock a sell.

About Mediwound Ltd (NASDAQ:MDWD)

MediWound Ltd. is a biopharmaceutical company focused on developing, manufacturing and commercializing products in the fields of severe burns, chronic and other hard-to-heal wounds, connective tissue disorders and other indications. The Company's biopharmaceutical product, NexoBrid, received marketing authorization from the European Union agency (EMA) and the Israeli and Argentinean ministries of health for removal of dead or damaged tissue, known as eschar, in adults with deep partial and full thickness thermal burns, also referred to as severe burns. NexoBrid is based on the Company's proteolytic enzyme technology. NexoBrid is a topically-applied product that removes eschar in approximately four hours without harming the surrounding healthy tissues. The Company offers NexoBrid in Europe and Israel. NexoBrid has been investigated in over 550 patients across approximately 15 countries and over four continents in approximately six completed Phase II and Phase III clinical studies.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with's FREE daily email newsletter.